Filtros de búsqueda

Lista de obras de

"Irinogenetics" and UGT1A: from genotypes to haplotypes

artículo científico publicado en 2004

5-Fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for malignant gliomas: a clinical and pharmacologic analysis

artículo científico publicado en 1993

5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy

artículo científico publicado en 1999

5-fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study ⬇️

artículo científico publicado el 1 de enero de 1992

A Cost-Focused Alternative Cancer Medication Dispensing Strategy-"Pack Splitting"

scientific article published on 17 October 2019

A New Liver Expression Quantitative Trait Locus Map From 1,183 Individuals Provides Evidence for Novel Expression Quantitative Trait Loci of Drug Response, Metabolic, and Sex-Biased Phenotypes

artículo científico publicado en 2019

A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance)

A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors

artículo científico publicado en 1999

A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma

artículo científico publicado en 2004

A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871.

artículo científico publicado en 2007

A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter.

artículo científico publicado en 2005

A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101.

artículo científico publicado en 2012

A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303

scientific journal article

A genome-wide integrative study of microRNAs in human liver

artículo científico publicado en 2013

A novel fully automated molecular diagnostic system (AMDS) for colorectal cancer mutation detection

artículo científico publicado en 2013

A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors

artículo científico publicado en 2018

A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469.

artículo científico publicado en 2014

A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine

artículo científico publicado en 2003

A pharmacogenetic study of vorinostat glucuronidation

artículo científico publicado en 2010

A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia

artículo científico publicado en 2014

A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia

artículo científico publicado en 2008

A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.

artículo científico publicado en 2003

A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours

artículo científico publicado en 2008

A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors

scientific article published on 11 April 2005

A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors

artículo científico publicado en 2004

A phase I study of cisplatin, 5-fluorouracil and leucovorin with escalating doses of hydroxyurea in chemotherapy naive patients ⬇️

artículo científico publicado el 1 de enero de 1991

A phase I study of continuous infusion cilengitide in patients with solid tumors ⬇️

artículo científico publicado el 14 de septiembre de 2010

A phase I study of intermittent infusion cladribine in patients with solid tumors

artículo científico publicado en 1994

A phase I study of liposomal doxorubicin (Doxil) with topotecan

artículo científico publicado en 2000

A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days

artículo científico publicado en 1999

A phase I study of sirolimus and bevacizumab in patients with advanced malignancies

artículo científico publicado en 2011

A phase I study of subcutaneous recombinant interleukin-2 and interferon alfa-2a

artículo científico publicado en 1993

A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer

artículo científico publicado en 2002

A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine

artículo científico publicado en 2004

A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661.

artículo científico publicado en 2002

A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases

artículo científico publicado en 2004

A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer

artículo científico publicado en 2004

A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital

artículo científico publicado en 2004

A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies

artículo científico publicado en 2009

A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer

artículo científico publicado en 1998

A programmable and implantable pumping system for systemic chemotherapy: a performance analysis in 52 patients

artículo científico publicado en 1987

A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer.

artículo científico publicado en 2016

A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer

artículo científico

A survey of the population genetic variation in the human kinome

artículo científico publicado en 2009

ABC transporter polymorphisms are associated with irinotecan pharmacokinetics and neutropenia

artículo científico publicado en 2016

Accelerated Approval of Anticancer Drugs: Lessons Learned from the Example of Olaratumab

scientific article published on 04 November 2020

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer

artículo científico publicado en 2011

Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung

scientific article published on 01 November 1987

Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability.

artículo científico publicado en 1989

Adoption of a clinical pharmacogenomics implementation program during outpatient care--initial results of the University of Chicago "1,200 Patients Project".

artículo científico publicado en 2014

Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients

artículo científico publicado en 1986

Alternative dosing regimens for atezolizumab: right dose, wrong frequency

artículo científico publicado en 2019

Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment

artículo científico publicado en 2009

An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance)

scientific article published on 01 August 2019

Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials.

artículo científico publicado en 2015

Analysis of comprehensive pharmacogenomic profiling to impact in-hospital prescribing

scientific article published on 01 February 2019

Analysis of the Yield of Phase II Combination Therapy Trials in Medical Oncology ⬇️

artículo científico publicado el 13 de septiembre de 2010

Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.

artículo científico publicado en 2018

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

artículo científico publicado en 2010

Applied Clinical Pharmacology in a Crisis - Interleukin-6 Axis Blockade and COVID-19

scientific article published on 02 June 2020

Assessment of Patient Knowledge and Perceptions of Pharmacogenomics Before and After Using a Mock Results Patient Web Portal

artículo científico publicado en 2019

Assessment of patient perceptions of genomic testing to inform pharmacogenomic implementation

artículo científico publicado en 2017

Assessment of provider-perceived barriers to clinical use of pharmacogenomics during participation in an institutional implementation study

scientific article published on 01 February 2019

Attitudes toward research participation and investigator conflicts of interest among advanced cancer patients participating in early phase clinical trials.

artículo científico publicado en 2007

Bar the windows but open the door to randomization

artículo científico publicado en 2010

Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).

artículo científico publicado en 2014

Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice

artículo científico publicado en 2002

Biomarkers in phase I oncology trials: signal, noise, or expensive distraction?

artículo científico publicado en 2007

Bootstrap validation of pharmacodynamic models defined via stepwise linear regression

artículo científico publicado en 1994

Burdensome Research Procedures in Trials: Why Less Is More

artículo científico publicado en 2017

COVIDOSE: A phase 2 clinical trial of low-dose tocilizumab in the treatment of non-critical COVID-19 pneumonia

artículo científico publicado en 2020

COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19

scientific article published on 26 July 2020

CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes

artículo científico publicado en 2004

CYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological quality

artículo científico publicado en 2013

Cancer chemotherapy and skin changes

artículo científico publicado en 1985

Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation

artículo científico publicado en 2010

Cancer pharmacogenomics: strategies and challenges

artículo científico publicado en 2013

Casting doubt on the scientific utility of post-treatment biopsies in phase 1 trials

artículo científico publicado en 2016

Challenges in interpreting the evidence for genetic predictors of ototoxicity

artículo científico publicado en 2013

Changes in peripheral blood and bone marrow specimens during and after alpha 2b-interferon therapy for hairy cell leukemia.

artículo científico publicado en 1987

Changes in peripheral blood and bone marrow specimens following therapy with recombinant alpha 2 interferon for hairy cell leukemia

artículo científico publicado en 1986

Chronic daily low dose of 4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione (Oltipraz) in patients with previously resected colon polyps and first degree female relatives of breast cancer patients

artículo científico publicado en 2000

Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion

artículo científico publicado en 2015

Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis

artículo científico publicado en 1993

Clarification regarding "phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties" and the accompanying commentary, "phase II cancer trials: out of c

artículo científico publicado en 2007

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy

artículo científico publicado en 2018

Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy

scientific article published on 11 July 2019

Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015

scientific article published on 06 May 2020

Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial.

artículo científico publicado en 2018

Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration

scientific article published on 01 September 1990

Clinical pharmacology of camptothecins.

artículo científico publicado en 1998

Clinical trial designs for cytostatic agents

artículo científico publicado en 2001

Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study.

artículo científico publicado en 2015

Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling

artículo científico publicado en 2016

Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases

artículo científico publicado en 2010

Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making

scientific article published on 01 February 2007

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics

artículo científico publicado en 2009

Conventional dosing of anticancer agents: precisely wrong or just inaccurate?

artículo científico publicado en 2014

Correction: Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients.

artículo científico publicado en 2014

Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with co

artículo científico publicado en 2002

Creating and evaluating genetic tests predictive of drug response

artículo científico publicado en 2008

Current dilemmas in carboplatin dosing

artículo científico publicado en 2011

Data modifications to phase I study of suramin

scientific article published on 01 September 1996

Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patient

artículo científico publicado en 2002

Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study

artículo científico publicado en 2004

Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee

artículo científico publicado en 2014

Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer

artículo científico publicado en 2007

Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors

artículo científico publicado en 2002

Determination of vinca alkaloids in human plasma by liquid chromatography/atmospheric pressure chemical ionization mass spectrometry

artículo científico publicado en 1997

Development of a schedule-dependent population pharmacodynamic model for rhizoxin without quantitation of plasma concentrations.

artículo científico publicado en 2000

Disease-drug database for pharmacogenomic-based prescribing

artículo científico publicado en 2016

Do Patients With Advanced Cancer Have the Ability to Make Informed Decisions for Participation in Phase I Clinical Trials?

Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer

artículo científico publicado en 2002

Dose-escalation models for combination phase I trials in oncology

artículo científico publicado el 4 de agosto de 2010

Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies

artículo científico publicado en 1996

Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer

artículo científico publicado en 2014

Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies

artículo científico publicado en 2004

Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies

artículo científico publicado en 2004

Drug-Drug Interactions With Oral Antineoplastic Agents

artículo científico publicado en 2017

Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests

artículo científico publicado en 2005

Durability of responses to interferon alfa-2b in advanced hairy cell leukemia

artículo científico publicado en 1987

Duration of response after interferon treatment of hairy cell leukemia

scientific article published on 01 June 1990

Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma

artículo científico publicado en 2008

EGFR pharmacogenomics: the story continues to mutate and evolve

artículo científico publicado en 2005

Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103).

artículo científico publicado en 2014

Effects of green tea compounds on irinotecan metabolism

artículo científico publicado en 2006

Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes

artículo científico publicado en 2005

Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis

artículo científico publicado en 2013

Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial

scientific article published on 18 December 2009

Elimination pathways of [14C]losoxantrone in four cancer patients

scientific article published on 01 February 2001

Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies

artículo científico publicado en 1995

Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies

article

Endostatin: are the 2 years up yet?

artículo científico publicado en 2002

Enhancing the Visibility and Prestige of Clinical Pharmacology as a Medical Subspecialty

scientific article published on 12 July 2019

Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7.

artículo científico publicado en 2001

Essential characteristics of pharmacogenomics study publications

Establishment of CYP2D6 reference samples by multiple validated genotyping platforms

artículo científico publicado en 2014

Estimation of Progression-Free Survival for All Treated Patients in the Randomized Discontinuation Trial Design

artículo científico publicado en 2012

Estimation of renal cell carcinoma treatment effects from disease progression modeling

artículo científico publicado en 2012

Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil

artículo científico publicado en 2002

Estimation of the glomerular filtration rate in cancer patients: a new formula for new drugs

artículo científico publicado en 2003

Ethical Framework for Including Research Biopsies in Oncology Clinical Trials: American Society of Clinical Oncology Research Statement

artículo científico publicado en 2019

Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials

artículo científico publicado en 2008

Etoposide combined with interferon alfa-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics

scientific article published on 01 March 1996

Etoposide pathway

artículo científico publicado en 2009

Evaluation of Leu-M5 (CD11c) in hairy cell leukemia by the alkaline phosphatase anti-alkaline phosphatase technique.

artículo científico publicado en 1988

Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients

artículo científico publicado en 2013

Evaluation of neuropathy in patients on suramin treatment

artículo científico publicado en 1997

Evaluation of utility of pharmacokinetic studies in phase I trials of two oncology drugs

artículo científico publicado en 2013

Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs.

artículo científico publicado en 2015

Exploring the relationship between polymorphic (TG/CA)n repeats in intron 1 regions and gene expression

artículo científico publicado en 2009

Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer

artículo científico publicado en 2018

Finding the right dose

scientific article published on 01 September 2003

First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors

artículo científico publicado en 2014

First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors

artículo científico publicado en 2015

Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study ⬇️

artículo científico publicado el 1 de enero de 1991

Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study

artículo científico publicado en 1993

Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea

scientific article published on 01 September 2000

Flow cytometry in hairy cell leukemia before and during interferon alfa-2b therapy

artículo científico publicado en 1987

Flushing oral oncology drugs down the toilet

artículo científico publicado en 2011

Forecasting unanticipated consequences of "The Sunshine Act": mostly cloudy

artículo científico publicado en 2014

From bedside to bench to bedside to clinical practice: an odyssey with irinotecan

artículo científico publicado en 2006

Functional EGFR Germline Polymorphisms May Confer Risk for EGFR Somatic Mutations in Non–Small Cell Lung Cancer, with a Predominant Effect on Exon 19 Microdeletions ⬇️

artículo científico publicado el 3 de febrero de 2011

Genetic factors affecting gene transcription and catalytic activity of UDP-glucuronosyltransferases in human liver

artículo científico publicado en 2014

Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing

artículo científico publicado en 2007

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

artículo científico publicado en 2004

Genetic variation determines VEGF-A plasma levels in cancer patients

artículo científico publicado en 2018

Genome-Wide Meta-Analysis Validates a Roless for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy

scientific article published on 20 June 2020

Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine

artículo científico publicado en 2016

Genome-wide identification of genetic determinants for the cytotoxicity of perifosine

artículo científico publicado en 2008

Genome-wide interrogation of longitudinal FEV1 in children with asthma

artículo científico publicado en 2014

Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy

artículo científico publicado en 2018

Genomic analysis of germline variation associated with survival of colorectal cancer patients treated with chemotherapy plus biologics in CALGB/SWOG 80405 (Alliance)

scientific article published on 21 September 2020

Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension

artículo científico publicado en 2008

Germline pharmacogenomics in oncology: decoding the patient for targeting therapy

artículo científico publicado en 2012

Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study

artículo científico publicado en 2013

Global gene expression as a function of germline genetic variation

artículo científico publicado en 2005

Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients

artículo científico publicado en 2013

Glucuronidation of OTS167 in Humans Is Catalyzed by UDP-Glucuronosyltransferases UGT1A1, UGT1A3, UGT1A8, and UGT1A10

artículo científico publicado en 2015

Granulocyte-macrophage--colony stimulating factor in metastatic renal cell carcinoma: a phase II trial

artículo científico publicado en 1998

Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.

artículo científico publicado en 2010

Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups

artículo científico publicado en 2002

Haplotypes of variants in the UDP-glucuronosyltransferase1A9 and 1A1 genes.

artículo científico publicado en 2005

Harmonization of Renal Function Assessment Is Needed During Early Clinical Development of Oncology Drugs

artículo científico publicado en 2015

Hepatocyte nuclear factor 1 regulates the expression of the organic cation transporter 1 via binding to an evolutionary conserved region in intron 1 of the OCT1 gene

artículo científico publicado en 2013

Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity

artículo científico publicado en 2004

Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities

artículo científico publicado en 1986

Human plasma pharmacokinetics of thiotepa following administration of high-dose thiotepa and cyclophosphamide

scientific article published on 01 July 1988

Hydroxyurea and etoposide: in vitro synergy and phase I clinical trial

artículo científico publicado en 1988

Hyponatremia and other toxic effects during a phase I trial of recombinant human gamma interferon and vinblastine.

artículo científico publicado en 1986

Ibrutinib's Cardiotoxicity-An Opportunity for Postmarketing Regulation

artículo científico publicado en 2020

Identification of a Genomic Region between and Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance)

artículo científico publicado en 2018

Identification of a variant in KDR associated with serum VEGFR2 and pharmacodynamics of Pazopanib

artículo científico publicado en 2014

Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue

artículo científico publicado en 2011

Immunotherapy and the A2A Adenosine Receptor: A Confounding Brew

scientific article published on 05 April 2019

Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee

artículo científico publicado en 2015

Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial

artículo científico publicado en 2020

Importance of food effects for oral oncology drugs

scientific article published on 01 June 2012

In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole ⬇️

artículo científico publicado el 1 de diciembre de 2010

In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes

artículo científico publicado en 2002

In vitro glucuronidation of aprepitant: a moderate inhibitor of UGT2B7.

artículo científico publicado en 2015

Inconsistent Labeling of Food Effect for Oral Agents across Therapeutic Areas: Differences between Oncology and Non-Oncology Products ⬇️

artículo científico publicado el 24 de agosto de 2010

Incorporating biomarkers into drug labeling

artículo científico publicado en 2014

Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender.

artículo científico publicado en 1996

Individualizing dosing of cancer chemotherapy.

artículo científico publicado en 1993

Individualizing dosing of irinotecan

artículo científico publicado en 2010

Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors ⬇️

artículo científico publicado el 1 de junio de 2011

Inside information: Financial conflicts of interest for research subjects in early phase clinical trials

artículo científico publicado en 2004

Institutional Profile: University of Chicago Center for Personalized Therapeutics: research, education and implementation science

artículo científico publicado en 2013

Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy

artículo científico publicado en 2012

Interactions between MDM2 and TP53 Genetic Alterations, and Their Impact on Response to MDM2 Inhibitors and Other Chemotherapeutic Drugs in Cancer Cells.

artículo científico publicado en 2009

Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism.

artículo científico publicado en 2003

Interferon Alfa-2b Antibodies and Clinical Resistance in a Patient with Hairy Cell Leukemia

artículo científico publicado en 1989

Interferon treatment for hairy cell leukemia. An update on a cohort of 69 patients treated from 1983 to 1986.

artículo científico publicado en 1994

Interferon treatment for hairy cell leukemia: an update on a cohort of 69 patients treated from 1983-1986

artículo científico publicado el 1 de noviembre de 1992

Interpatient and intrapatient variability in vinblastine pharmacokinetics

artículo científico publicado en 1987

Interpreting P values in pharmacogenetic studies: a call for process and perspective

artículo científico publicado en 2007

Interpreting disparate responses to cancer therapy: the role of human population genetics

artículo científico publicado en 2006

Interventional Pharmacoeconomics

artículo científico publicado en 2020

Interventional Pharmacoeconomics-A New Discipline for a Cost-Constrained Environment

article by Mark J Ratain et al published 20 June 2019 in JAMA Oncology

Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value

scientific article published on 16 April 2020

Intraindividual Pharmacokinetic Variability: Focus on Small-Molecule Kinase Inhibitors.

artículo científico publicado en 2017

Introduction by the Guest Editors

artículo científico publicado en 2020

Irinogenetics: what is the right star?

artículo científico publicado en 2006

Irinotecan dosing: does the CPT in CPT-11 stand for "Can't Predict Toxicity"?

artículo científico publicado en 2002

Irinotecan treatment in cancer patients with UGT1A1 polymorphisms

artículo científico publicado en 2003

Keratoacanthomas and skin neoplasms associated with suramin therapy

artículo científico publicado en 1996

Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance).

artículo científico publicado en 2017

Laboratory and clinical studies of biochemical modulation by hydroxyurea

artículo científico publicado el 1 de junio de 1992

Lack of association between common polymorphisms in UGT1A9 and gene expression and activity

artículo científico publicado en 2007

Learning from our patients: one participant's impact on clinical trial research and informed consent.

artículo científico publicado en 1997

Limited sampling model for area under the concentration time curve of total topotecan

artículo científico publicado en 1996

Limited sampling model for vinblastine pharmacokinetics

scientific article published on 01 October 1987

Limited sampling models for amonafide (NSC 308847) pharmacokinetics ⬇️

artículo científico publicado el 15 de julio de 1988

Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity

artículo científico publicado en 1996

Linkage disequilibrium across the UGT1A locus should not be ignored in association studies of cancer susceptibility

artículo científico publicado en 2005

Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.

artículo científico publicado en 2014

Low Dose Interferon Alfa-2B for the Induction of Remission of Hairy Cell Leukemia: A Multi-institutional Study of 49 Patients

artículo científico publicado en 1991

Low-Dose Abiraterone With Food: Rebutting an Editorial

artículo científico publicado en 2018

Low-dose interferon alfa-2b in the treatment of hairy cell leukemia

scientific article published on 01 August 1989

Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST).

scientific article published on 07 October 2016

Measuring response in a post-RECIST world: from black and white to shades of grey

artículo científico publicado en 2006

Merrill Jon Egorin, MD, 1948-2010.

artículo científico publicado en 2011

Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea

artículo científico publicado en 1994

Metabolism of megestrol acetate in vitro and the role of oxidative metabolites

artículo científico publicado en 2017

Might cigarettes be a "smoking gun" to reduce taxane myelotoxicity?

artículo científico publicado en 2012

Mineralocorticoid insufficiency due to suramin therapy

artículo científico publicado en 1996

Model-guided determination of maximum tolerated dose in phase I clinical trials: evidence for increased precision

artículo científico publicado en 1993

Modeling interpatient pharmacodynamic variability of etoposide.

artículo científico publicado en 1991

Models of excellence: improving oncology drug development

artículo científico publicado en 2012

Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital

scientific article published on 01 January 1997

Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer

artículo científico publicado en 2005

Modulation of vinblastine resistance with cyclosporine: a phase I study

artículo científico publicado en 1993

New feature: pathways and important genes from PharmGKB

artículo científico publicado en 2009

New perspectives on the toxicity of etoposide.

artículo científico publicado en 1992

New phase I trial methodology

artículo científico publicado en 1997

Nonlinear population pharmacokinetics of sirolimus in patients with advanced cancer

artículo científico publicado en 2012

Nonprofit biomedical companies.

artículo científico publicado en 2008

O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings

artículo científico publicado en 1998

Obviating the Need for Serial Biopsies Through Random Assignment

artículo científico publicado en 2016

Oncology micro-cap stocks: caveat emptor!

artículo científico publicado en 2011

Oncology's "Hockey Stick" Moment for the Cost of Cancer Drugs-The Climate Is About to Change

artículo científico publicado en 2020

Opportunities and challenges in the development of experimental drug combinations for cancer

artículo científico publicado en 2011

Opportunities for using In Silico-Based Extended Dosing Regimens for Monoclonal Antibody Immune Checkpoint Inhibitors

scientific article published on 18 May 2020

Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients

scientific article published on 17 March 2020

Optimising the design of phase II oncology trials: the importance of randomisation.

artículo científico publicado en 2008

Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies

artículo científico publicado en 2009

Paradoxical relationship between acetylator phenotype and amonafide toxicity

artículo científico publicado en 1991

Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance).

artículo científico publicado en 2015

Patient Perceptions of Care as Influenced by a Large Institutional Pharmacogenomic Implementation Program

artículo científico publicado en 2016

Patient insights on features of an effective pharmacogenomics patient portal

artículo científico publicado en 2020

Patient-provider communications about pharmacogenomic results increase patient recall of medication changes

artículo científico publicado en 2019

Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment

artículo científico publicado en 2002

Perceptions of cancer patients and their physicians involved in phase I trials

artículo científico publicado en 1995

Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance)

scientific article published on 04 December 2019

Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan

artículo científico publicado en 2009

Pharmacodynamic modeling of prolonged administration of etoposide.

artículo científico publicado en 1996

Pharmacodynamics and long-term toxicity of etoposide

artículo científico publicado en 1994

Pharmacodynamics in cancer therapy

artículo científico

Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer

scientific article published on 01 May 1996

Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy

artículo científico publicado en 2016

Pharmacogenetic pathway analysis of irinotecan

scientific article published on 16 April 2008

Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?

artículo científico publicado en 2008

Pharmacogenetics and cancer chemotherapy

artículo científico publicado en 1998

Pharmacogenetics and pharmacogenomics of anticancer agents.

artículo científico publicado en 2009

Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan.

artículo científico publicado en 2001

Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping

artículo científico publicado en 2006

Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity

artículo científico publicado en 2008

Pharmacogenomic considerations for medications in the perioperative setting

artículo científico publicado en 2019

Pharmacogenomic genotypes define genetic ancestry in patients and enable population-specific genomic implementation

artículo científico publicado en 2019

Pharmacogenomic-Based Decision-Support to Predict Adherence to Medications

scientific article published on 31 March 2020

Pharmacogenomics and patient care: one size does not fit all.

artículo científico publicado en 2012

Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing

artículo científico publicado en 2017

Pharmacogenomics: challenges and opportunities

artículo científico publicado en 2006

Pharmacogenomics: road to anticancer therapeutics nirvana? ⬇️

artículo científico publicado el 29 de septiembre de 2003

Pharmacogenomics: will the promise be fulfilled?

artículo científico publicado en 2010

Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients

artículo científico publicado en 1997

Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A.

artículo científico publicado en 1996

Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer

scientific article published on 17 February 2007

Pharmacokinetic variability of anticancer agents

artículo científico publicado en 2005

Pharmacokinetics and pharmacodynamics of 9-aminocamptothecin infused over 72 hours in phase II studies

artículo científico publicado en 1999

Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin

artículo científico publicado en 1989

Pharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agent

artículo científico publicado en 1995

Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study

artículo científico publicado en 2005

Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity

artículo científico publicado en 1991

Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).

artículo científico publicado en 1997

Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors

artículo científico publicado en 2003

Phase I Study of an Oral Formulation of ZD9331 Administered Daily for 28 Days ⬇️

artículo científico publicado el 1 de mayo de 2003

Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).

artículo científico publicado en 1994

Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101

artículo científico publicado en 2007

Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301

artículo científico publicado en 2009

Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565.

artículo científico publicado en 2000

Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264.

artículo científico publicado en 1998

Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study

artículo científico publicado en 1998

Phase I and pharmacological study of vinblastine by prolonged continuous infusion

artículo científico publicado en 1986

Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer

artículo científico publicado en 2001

Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071)

artículo científico publicado en 1998

Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.

artículo científico publicado en 2002

Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer

scientific article published on 01 April 1998

Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer

scientific article published on 01 August 2000

Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer ⬇️

artículo científico publicado el 15 de marzo de 1993

Phase I clinical and pharmacological study of thymidine (NSC 21548) and cis-diamminedichloroplatinum(II) in patients with advanced cancer.

artículo científico publicado en 1986

Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion

artículo científico publicado en 1993

Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors

artículo científico publicado en 2004

Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies

artículo científico publicado en 2014

Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients

artículo científico publicado en 2012

Phase I study of 3′-deamino-3′-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762, PNU 152243) administered on a daily ×3 schedule ⬇️

artículo científico publicado el 1 de agosto de 1997

Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations

artículo científico publicado en 2001

Phase I study of adozelesin administered by 24-hour continuous intravenous infusion

artículo científico publicado en 1994

Phase I study of amonafide dosing based on acetylator phenotype.

artículo científico publicado en 1993

Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck

artículo científico publicado en 1998

Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer

artículo científico publicado en 1999

Phase I study of escalating does of carboplatin

artículo científico publicado en 1994

Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte-macrophage colony stimulating factor support

scientific article published on 01 June 1996

Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs

artículo científico publicado en 2007

Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule

artículo científico publicado en 2017

Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study

artículo científico publicado en 1995

Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors

artículo científico publicado en 2001

Phase I study of suramin administered by intermittent infusion without adaptive control to cancer patients: update of two expanded dose levels near the maximally tolerated dose

artículo científico publicado en 1996

Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer ⬇️

artículo científico publicado el 1 de septiembre de 1995

Phase I study of the combination of losoxantrone and cyclophosphamide in patients with refractory solid tumours

artículo científico publicado en 2002

Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia.

artículo científico publicado en 2008

Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin

artículo científico publicado en 1997

Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies

artículo científico publicado en 2001

Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies.

artículo científico publicado en 1994

Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2.

artículo científico publicado en 1998

Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study

scientific article published on 01 August 1993

Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor

scientific article published on 01 January 2005

Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer.

artículo científico publicado en 1998

Phase II oncology trials: let's be positive

artículo científico publicado en 2005

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

artículo científico publicado en 2006

Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours

artículo científico publicado en 2019

Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST

artículo científico publicado en 2004

Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551.

artículo científico publicado en 2008

Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer

artículo científico publicado en 1998

Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties

scientific article published on 01 April 2007

Phase-I trial of Thiotepa, granulocyte-macrophage colony-stimulating factor and prednisone or pentoxifylline in patients with refractory solid tumors.

artículo científico publicado en 1994

Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism

scientific article published on 01 May 1999

Physician-determined patient risk of toxic effects: impact on enrollment and decision making in phase I cancer trials.

artículo científico publicado en 1994

Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion

artículo científico publicado en 1989

Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study

scientific article published on 01 March 1995

Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide

artículo científico publicado en 2002

Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751.

artículo científico publicado en 2013

Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans

artículo científico publicado en 2008

Prescribing oral chemotherapy

artículo científico publicado en 2007

Preventing adverse drug-drug interactions: a need for improved data and logistics

artículo científico publicado en 2013

Prognostic factors for survival in patients treated in phase I clinical trials

scientific article published on 01 October 1994

Prognostic variables in hairy cell leukemia after splenectomy as initial therapy

artículo científico publicado en 1988

Prolonged Pharmacokinetic Interaction Between Capecitabine and a CYP2C9 Substrate, Celecoxib

artículo científico publicado en 2019

Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer

artículo científico publicado en 2018

Prospective evaluation of body surface area as a determinant of paclitaxel pharmacokinetics and pharmacodynamics in women with solid tumors: Cancer and Leukemia Group B Study 9763

artículo científico publicado en 2004

Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762)

scientific article published on 27 March 2006

Providing Balance in ASCO Clinical Practice Guidelines: CYP2D6 Genotyping and Tamoxifen Efficacy

scientific article published on 01 November 2016

Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.

artículo científico publicado en 2004

R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9.

scientific article published on 21 May 2009

RECIST: no longer the sharpest tool in the oncology clinical trials toolbox---point

Randomized discontinuation design: application to cytostatic antineoplastic agents

artículo científico publicado en 2002

Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?

artículo científico publicado en 2005

Randomized phase II trials: a long-term investment with promising returns

artículo científico publicado en 2011

Randomized study of the duration of treatment with interferon alfa-2B in patients with hairy cell leukemia

artículo científico publicado en 1988

Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.

artículo científico publicado en 2002

Rapid response of B-cell prolymphocytic leukemia to 2-chlorodeoxyadenosine ⬇️

artículo científico publicado el 1 de noviembre de 1992

Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.

artículo científico publicado en 2012

Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.

artículo científico publicado en 2014

Recommended changes to oncology clinical trial design: revolution or evolution?

artículo científico publicado en 2007

Redefining the primary objective of phase I oncology trials

scientific article published on 09 September 2014

Relapse after interferon alfa-2b therapy for hairy-cell leukemia: analysis of prognostic variables

scientific article published on 01 November 1988

Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines

artículo científico publicado en 2007

Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer

artículo científico publicado en 2004

Reply to I.F. Tannock, P. Isaacsson Velho et al, M. Tiako Meyo et al, and F.J.S.H. Woei-A-Jin et al

scientific article published on 06 September 2018

Reply to T.A. Yap et al

scientific article published on 02 May 2016

Report of a multi-institutional study of 193 patients with hairy cell leukemia treated with interferon-alfa2b

artículo científico publicado en 1988

Resampling phase III data to assess phase II trial designs and endpoints

artículo científico publicado en 2012

Response to high dose cyclophosphamide with GM-CSF in Merkel cell tumor

artículo científico publicado en 1991

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors

artículo científico publicado en 2018

Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab-Letter

artículo científico publicado en 2020

Searching for tissue-specific expression pattern-linked nucleotides of UGT1A isoforms

artículo científico publicado en 2007

Sequential evaluation of alpha-2b-interferon treatment in 128 patients with hairy cell leukemia

artículo científico publicado en 1987

Sequential therapy with dacarbazine and carmustine: a phase I study

artículo científico publicado en 1994

Sequential treatment of hairy cell leukemia: a new role for interferon.

artículo científico

Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide

artículo científico publicado en 2015

Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia ⬇️

artículo científico publicado el 15 de noviembre de 1990

Simplifying the use of pharmacogenomics in clinical practice: Building the genomic prescribing system

artículo científico publicado en 2017

Simultaneous determination of 5-fluorouracil and uracil by high-performance liquid chromatography using four serial columns

artículo científico publicado en 1998

Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene

artículo científico publicado en 2008

Skeletal complications in hairy cell leukemia: diagnosis and therapy ⬇️

artículo científico publicado el 1 de agosto de 1988

Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies

artículo científico publicado en 2014

Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents

artículo científico publicado en 1993

Statistical approaches to pharmacodynamic modeling: motivations, methods, and misperceptions

artículo científico publicado en 1993

Study of cohort-specific consent and patient control in phase I cancer trials.

artículo científico publicado en 1998

Study of the genetic determinants of UGT1A1 inducibility by phenobarbital in cultured human hepatocytes

artículo científico publicado en 2006

Subcutaneously Administered Recombinant Human Interleukin-2 and Interferon Alfa-2a for Advanced Breast Cancer: A Phase II study of the Cancer and Leukemia Group B (CALGB 9041)

scientific article published on 01 January 2004

Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901.

artículo científico publicado en 2005

Suramin: is adaptive control necessary? ⬇️

artículo científico publicado el 1 de diciembre de 1992

Survival Experience of 195 Patients with Hairy Cell Leukemia Treated in a Multi-Institutional Study with Interferon-Alfa 2B.

artículo científico publicado en 1991

TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?

artículo científico publicado en 2006

Taking a Measured Approach to Toxicity Data in Phase I Oncology Clinical Trials

artículo científico publicado en 2015

Targeted therapies: redefining the primary objective of phase I oncology trials

artículo científico publicado en 2014

Terminal ballistics of kinase inhibitors: there are no magic bullets

artículo científico publicado en 2006

Testing the wrong hypothesis in phase II oncology trials: there is a better alternative

artículo científico publicado en 2007

The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics

artículo científico publicado en 2012

The HapMap Resource is Providing New Insights into Ourselves and its Application to Pharmacogenomics.

artículo científico publicado en 2008

The ImPreSS Trial: Implementation of Point-of-Care Pharmacogenomic Decision Support in Perioperative Care

artículo científico publicado en 2019

The Molecular Profiling Lottery: More Accuracy, Less Precision, and No Cost

scientific article published on 04 December 2018

The Outlier in All of Us: Why Implementing Pharmacogenomics Could Matter for Everyone

artículo científico publicado en 2016

The Role of Early-Phase Design-Letter

artículo científico publicado en 2019

The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation.

artículo científico publicado en 2010

The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds

artículo científico publicado en 2008

The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective

artículo científico publicado en 2006

The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee

artículo científico publicado en 2010

The development of a financial toxicity patient-reported outcome in cancer: The COST measure

artículo científico publicado en 2014

The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients

artículo científico publicado en 2011

The impact of industry on oncology research and practice

artículo científico

The investigational drug steering committee

artículo científico publicado en 2007

The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance).

artículo científico publicado en 2013

The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity

scientific article published on 01 January 2007

The role of interferon in the treatment of hairy cell leukemia

artículo científico publicado en 1986

The role of pharmacogenetics in cancer therapeutics

artículo científico publicado en 2006

The treatment of hairy cell leukemia: an update

artículo científico publicado en 1992

The value meal: how to save $1,700 per month or more on lapatinib

artículo científico publicado en 2007

The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation

artículo científico publicado en 2018

Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer

scientific article published on 01 February 1997

Time Is Money: Optimizing the Scheduling of Nivolumab

scientific article published on 27 August 2018

Time to tumor growth: a model end point and new metric system for oncology clinical trials

artículo científico publicado en 2013

Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients

artículo científico publicado en 1991

Treatment of hairy cell leukemia with recombinant alpha 2 interferon

artículo científico publicado en 1985

Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel

scientific article published on 01 June 1996

Troxacitabine in patients with refractory leukemia

artículo científico publicado en 2002

Tumour heterogeneity in the clinic

artículo científico publicado en 2013

Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies

artículo científico publicado en 2011

UGT pharmacogenomics: implications for cancer risk and cancer therapeutics

scientific article published on 01 August 2003

UGT1A and UGT2B genetic variation alters nicotine and nitrosamine glucuronidation in european and african american smokers

artículo científico publicado en 2014

UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers

scientific article published on 01 August 2007

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

artículo científico publicado en 2002

Unmet needs in preventing adverse drug-drug interactions

artículo científico publicado en 2013

Unsupported off-label chemotherapy in metastatic colon cancer

artículo científico publicado en 2012

Update on pharmacogenetics in cancer chemotherapy

artículo científico publicado en 2002

Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy

artículo científico publicado en 2010

User beware: we need more science and less art when measuring financial toxicity in oncology

artículo científico publicado en 2015

Value-based insurance design in oncology

scientific article published on 01 April 2011

Value-based insurance design: aligning incentives, benefits, and evidence in oncology

artículo científico publicado en 2012

Vascular endothelial growth factor pathway

scientific article published on May 2010

Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance)

artículo científico publicado en 2014

Vemurafenib oral bioavailability: an insoluble problem

artículo científico publicado en 2014

Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.

artículo científico publicado en 2003

Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19

scientific article published on 27 May 2020

What is the choice of treatment for hairy cell leukemia?

scientific article published on 01 February 1989

Why RECIST works and why it should stay--reply to counterpoint

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda